Rebecca S Pettit1, Natalie Neu2, Jeffrey J Cies3, Craig Lapin4, Marianne S Muhlebach5, Kimberly J Novak6, Sean T Nguyen7, Lisa Saiman2, David P Nicolau8, Joseph L Kuti9. 1. Department of Pharmacy, Riley Hospital for Children, Indianapolis, IN, USA. 2. Department of Pediatrics, Division of Infectious Diseases, Columbia University Medical Center and New York-Presbyterian Morgan Stanley Children's Hospital, New York, NY, USA. 3. Department of Pharmacy, St. Christopher's Hospital for Children, Philadelphia, PA, USA. 4. Pediatric Pulmonology, Connecticut Children's Medical Center, Hartford, CT, USA. 5. Pediatric Pulmonology, University of North Carolina, Chapel Hill, NC, USA. 6. Department of Pharmacy, Nationwide Children's Hospital, Columbus, OH, USA. 7. Department of Pharmacy, Children's Medical Center, Dallas, TX, USA. 8. Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA. 9. Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA joseph.kuti@hhchealth.org.
Abstract
OBJECTIVES: Meropenem is frequently used to treat pulmonary exacerbations in children with cystic fibrosis (CF) in the USA. Prolonged-infusion meropenem improves the time that free drug concentrations remain above the MIC (fT> MIC) in adults, but data in CF children are sparse. We describe the population pharmacokinetics, tolerability and treatment burden of prolonged-infusion meropenem in CF children. METHODS: Thirty children aged 6-17 years with a pulmonary exacerbation received 40 mg/kg meropenem every 8 h; each dose was administered as a 3 h infusion. Pharmacokinetics were determined using population methods in Pmetrics. Monte Carlo simulation was employed to compare 0.5 with 3 h infusions to estimate the probability of pharmacodynamic target attainment (PTA) at 40% fT> MIC. NCT#01429259. RESULTS: A two-compartment model fitted the data best with clearance and volume predicted by body weight. Clearance and volume of the central compartment were 0.41 ± 0.23 L/h/kg and 0.30 ± 0.17 L/kg, respectively. Half-life was 1.11 ± 0.38 h. At MICs of 1, 2 and 4 mg/L, PTAs for the 0.5 h infusion were 87.6%, 70.1% and 35.4%, respectively. The prolonged infusion increased PTAs to >99% for these MICs and achieved 82.8% at 8 mg/L. Of the 30 children, 18 (60%) completed treatment with prolonged infusion; 5 did so at home without any reported burden. Nine patients were changed to a 0.5 h infusion when discharged home. CONCLUSIONS: In these CF children, meropenem clearance was greater compared with published values from non-CF children. Prolonged infusion provided an exposure benefit against pathogens with MICs ≥1 mg/L, was well tolerated and was feasible to administer in the hospital and home settings, the latter depending on perception and family schedule.
OBJECTIVES:Meropenem is frequently used to treat pulmonary exacerbations in children with cystic fibrosis (CF) in the USA. Prolonged-infusion meropenem improves the time that free drug concentrations remain above the MIC (fT> MIC) in adults, but data in CF children are sparse. We describe the population pharmacokinetics, tolerability and treatment burden of prolonged-infusion meropenem in CF children. METHODS: Thirty children aged 6-17 years with a pulmonary exacerbation received 40 mg/kg meropenem every 8 h; each dose was administered as a 3 h infusion. Pharmacokinetics were determined using population methods in Pmetrics. Monte Carlo simulation was employed to compare 0.5 with 3 h infusions to estimate the probability of pharmacodynamic target attainment (PTA) at 40% fT> MIC. NCT#01429259. RESULTS: A two-compartment model fitted the data best with clearance and volume predicted by body weight. Clearance and volume of the central compartment were 0.41 ± 0.23 L/h/kg and 0.30 ± 0.17 L/kg, respectively. Half-life was 1.11 ± 0.38 h. At MICs of 1, 2 and 4 mg/L, PTAs for the 0.5 h infusion were 87.6%, 70.1% and 35.4%, respectively. The prolonged infusion increased PTAs to >99% for these MICs and achieved 82.8% at 8 mg/L. Of the 30 children, 18 (60%) completed treatment with prolonged infusion; 5 did so at home without any reported burden. Nine patients were changed to a 0.5 h infusion when discharged home. CONCLUSIONS: In these CF children, meropenem clearance was greater compared with published values from non-CF children. Prolonged infusion provided an exposure benefit against pathogens with MICs ≥1 mg/L, was well tolerated and was feasible to administer in the hospital and home settings, the latter depending on perception and family schedule.
Authors: Dagan O Lonsdale; Emma H Baker; Karin Kipper; Charlotte Barker; Barbara Philips; Andrew Rhodes; Mike Sharland; Joseph F Standing Journal: Br J Clin Pharmacol Date: 2018-11-26 Impact factor: 4.335
Authors: Hajira Bilal; Phillip J Bergen; Jessica R Tait; Steven C Wallis; Anton Y Peleg; Jason A Roberts; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Natalia Sutiman; Janine Cynthia Koh; Kevin Watt; Christoph Hornik; Beverly Murphy; Yoke Hwee Chan; Jan Hau Lee Journal: Front Pediatr Date: 2020-06-26 Impact factor: 3.418